Senti Biosciences Raises $53 Million from Amgen and Others in Series A Financing Post author:Sam Post published:February 26, 2018 Post category:BioPharma Senti Biosciences, based in South San Francisco, has completed a $53 million Series A financing. Source: BioSpace You Might Also Like GSK Is Now Favorite to Acquire Pfizer's Consumer Health Business March 21, 2018 Why Amgen Needs an Acquisition to Keep Up with Immuno-Oncology Competitors July 9, 2017 Aldeyra Reports Full Year 2016 Financial Results March 30, 2017